Lynx1 Capital Management LP (CIK 1910456) reported 21 SEC Form 4 insider transactions across 5 companies over the past 18 months (most recent 2026-04-02). Recent activity: Buy KRRO (520 shares), Buy TCRX (75,500 shares), Buy TCRX (6,232 shares), Buy TCRX (80,069 shares), Buy CGEM (165,667 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | Korro Bio, Inc. (KRRO) | Insider | Buy | 520 | $5,512 |
| 2025-12-23 | TScan Therapeutics, Inc. (TCRX) | Insider | Buy | 75,500 | $67,950 |
| 2025-12-23 | TScan Therapeutics, Inc. (TCRX) | Insider | Buy | 6,232 | $5,609 |
| 2025-12-23 | TScan Therapeutics, Inc. (TCRX) | Insider | Buy | 80,069 | $72,062 |
| 2025-10-30 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 165,667 | $1.4M |
| 2025-10-23 | Neuphoria Therapeutics Inc. (NEUP) | Insider | Buy | 639,110 | $3.3M |
| 2025-10-21 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 15,032 | $114,093 |
| 2025-10-21 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 51,500 | $408,910 |
| 2025-10-21 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 150,000 | $1.3M |
| 2025-10-21 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 32,217 | $252,581 |
| 2025-10-10 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 556,300 | $3.6M |
| 2025-10-10 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 626,043 | $4.2M |
| 2025-10-10 | Cullinan Therapeutics, Inc. (CGEM) | Insider | Buy | 277,298 | $2.0M |
| 2025-09-15 | Passage BIO, Inc. (PASG) | Insider | Buy | 325 | $2,262 |
| 2025-09-15 | Passage BIO, Inc. (PASG) | Insider | Buy | 19,783 | $138,283 |
| 2025-09-15 | Passage BIO, Inc. (PASG) | Insider | Buy | 11,900 | $83,181 |
| 2025-07-24 | Passage BIO, Inc. (PASG) | Insider | Buy | 13,123 | $71,389 |
| 2025-07-24 | Passage BIO, Inc. (PASG) | Insider | Buy | 49,302 | $282,993 |
| 2025-07-24 | Passage BIO, Inc. (PASG) | Insider | Buy | 66,423 | $379,275 |
| 2025-05-21 | TScan Therapeutics, Inc. (TCRX) | Insider | Buy | 1.2M | $1.4M |
| 2025-05-21 | TScan Therapeutics, Inc. (TCRX) | Insider | Buy | 1.4M | $1.7M |
Source: SEC Form 4 filings · as of 2026-04-02